Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INAB 
In8bio Inc (INAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $46.9
1 Year Target Price $46.9
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.4% | Avg. Invested days 16 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.58M USD | Price to earnings Ratio - | 1Y Target Price 46.9 |
Price to earnings Ratio - | 1Y Target Price 46.9 | ||
Volume (30-day avg) 4 | Beta 0.03 | 52 Weeks Range 1.91 - 16.71 | Updated Date 10/17/2025 |
52 Weeks Range 1.91 - 16.71 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.05% | Return on Equity (TTM) -165.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 287951 | Price to Sales(TTM) - |
Enterprise Value 287951 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.15 | Shares Outstanding 4539717 | Shares Floating 4182441 |
Shares Outstanding 4539717 | Shares Floating 4182441 | ||
Percent Insiders 5.56 | Percent Institutions 19.29 |
Upturn AI SWOT
In8bio Inc
Company Overview
History and Background
In8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer. Founded in 2016, it leverages its DeltEx platform to develop allogeneic and autologous cell therapies. Significant milestones include advancing multiple DeltEx programs into clinical trials.
Core Business Areas
- DeltEx Platform: In8bio's DeltEx platform is the core of their business, focusing on genetically engineering and expanding gamma-delta T cells to target and kill cancer cells.
- Allogeneic Gamma-Delta T Cell Therapies: Developing off-the-shelf cell therapies for a broader patient population.
- Autologous Gamma-Delta T Cell Therapies: Developing personalized cell therapies using a patient's own cells.
Leadership and Structure
The leadership team includes Trishna Goswami, PhD, as CEO, and Lawrence Lamb, PhD, as CSO. The company has a scientific advisory board and operates with a typical biopharmaceutical organizational structure, focusing on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- INB-400: An autologous DeltEx product candidate in Phase 2 trials for glioblastoma multiforme (GBM). Market share is currently negligible as it's in development. Competitors include larger pharmaceutical companies developing CAR-T therapies for solid tumors.
- INB-200: An allogeneic DeltEx product candidate in Phase 1 trials for hematological malignancies. Market share is also currently negligible. Competitors include companies developing allogeneic CAR-T therapies and other immunotherapy approaches.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and personalized medicine. It's highly competitive and capital-intensive.
Positioning
In8bio is positioned as an innovator in the gamma-delta T cell therapy space. Its DeltEx platform provides a competitive advantage in engineering and expanding these cells.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is projected to reach billions of dollars. In8bio is positioned to capture a portion of this market by addressing unmet needs in solid tumors and hematological malignancies.
Upturn SWOT Analysis
Strengths
- Proprietary DeltEx platform
- Strong scientific leadership
- Focus on gamma-delta T cell therapies
- Clinical-stage pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- High development risk inherent in biotechnology
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Advancements in cell therapy manufacturing
- Positive clinical trial data
Threats
- Competition from other cell therapy companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- CRIS (CRISPR Therapeutics AG)
- PFE (Pfizer Inc.)
- BMY (Bristol-Myers Squibb)
Competitive Landscape
In8bio's advantage lies in its focus on gamma-delta T cells, potentially offering improved safety and efficacy compared to alpha-beta T cell therapies. However, it faces significant competition from larger companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing pipeline programs through preclinical and early clinical stages. However, it's not easy to quantifies in numerical formats.
Future Projections: Future growth depends on clinical trial outcomes and potential partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and presenting data at scientific conferences.
Summary
In8bio is a clinical-stage biopharmaceutical company pioneering gamma-delta T cell therapies. Their DeltEx platform is a key strength. Success hinges on positive clinical trial results and strategic partnerships. The company's small size and financial constraints pose challenges in a competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About In8bio Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Mr. Tai-Wei Ho | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://in8bio.com |
Full time employees 18 | Website https://in8bio.com | ||
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.